An observational study in Chronic Kidney Disease 5D and Secondary Hyperparathyroidism, sponsored by Boryung Pharmaceutical Co., Ltd. Recruiting at 1 site in Korea, Republic of. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2024-12-12.
Sponsored by Boryung Pharmaceutical Co., Ltd · Observational
The purpose of this study is to evaluate the efficacy and safety of pacitol Inj.(paricalcitol) for secondary hyperparathyroidism with stage 5D chronic kidney disease (CKD 5D) receiving hemodialysis
188 studies on the registry are indexed under Hyperparathyroidism, Secondary; 15 are open to participants now.
This study's planned enrollment of 1,000 is above the median of 131 across 34 observational studies indexed under Hyperparathyroidism, Secondary.
Browse Hyperparathyroidism, Secondary studies →Boryung Pharmaceutical Co., Ltd is the lead sponsor of 143 studies on the registry; 23 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Hemodialysis patients with secondary hyperparathyroidism due to chronic kidney disease(CKD 5D)
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Proportion of subjects whose intact parathyroid hormone level applies to the therapeutic area(CKD 5D)
Time frame: 12 weeks after administration
Proportion of subjects whose intact parathyroid hormone level applies to the therapeutic area(CKD 5D)
Time frame: 24 weeks after administration
Proportion of subjects whose intact parathyroid hormone level decreased by more than 30%
Time frame: 12, 24 weeks compared to pre-dose
Incidence of anemia
Time frame: From baseline to 12 weeks or 24 weeks
Change in intact parathyroid hormone
Time frame: 12, 24 weeks compared to pre-dose
Change in Calcium X Phosphorus
Time frame: 12, 24 weeks after administration
Plan to share: No
No publications or documents are linked to this record.
Started Oct 2023 (actual). Primary completion is estimated for Apr 2026, 30 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Hyperparathyroidism, Secondary →
Boryung Pharmaceutical Co., Ltd →